Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 5Phase 1/2 3Phase 3 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 4Gynecologic 2

Conditions

Ovarian Neoplasms 225Uterine Cervical Neoplasms 181Fallopian Tube Neoplasms 93Carcinoma, Ovarian Epithelial 85Endometrial Neoplasms 74Neoplasms 37Uterine Cervical Dysplasia 35Papillomavirus Infections 35Breast Neoplasms 26Peritoneal Neoplasms 25Vulvar Neoplasms 23Condylomata Acuminata 22Vaginal Neoplasms 18Recurrence 16Testicular Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Burkitt Lymphoma 12Brenner Tumor 12Primary Myelofibrosis 11Multiple Myeloma 11Lymphoma, Non-Hodgkin 11Lymphoma, Mantle-Cell 11Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Chronic-Phase 11Leukemia, Myeloid, Accelerated Phase 11Leukemia, Lymphocytic, Chronic, B-Cell 11Blast Crisis 11

Interventions

Taxes 2Paclitaxel 2Carboplatin 2pembrolizumab 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinosarcoma × Gynecologic × Clear all
NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
813 enrolled 16 charts 1 FDA
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT00954174 2021-09-30

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

GOG Foundation

Phase 3 Unknown
637 enrolled 18 charts
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡